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Abstract Arsenic trioxide (ATO) is an efficient drug for the
treatment of the patients with acute promyelocytic leukemia
(APL). Inhibition of proliferation as well as apoptosis, atten-
uation of migration, and induction of differentiation in tumor
cells are the main mechanisms through which ATO acts
against APL. Despite advantages of ATO in treatment of some
malignancies, certain harmful side effects, such as
cardiotoxicity, have been reported. It has been well document-
ed that morphine has antioxidant, anti-apoptotic, and
cytoprotective properties and is able to attenuate cytotoxicity.
Therefore, in this study, we aimed to investigate the protective
effects of morphine against ATO toxicity in H9c2 myocytes
using multi-parametric assay including thiazolyl blue tetrazo-
lium bromide (MTT) assay, reactive oxygen species (ROS)
generation, caspase 3 activity, nuclear factor kappa B
(NF-κB) phosphorylation assay, and expression of apoptotic
markers. Our results showed that morphine (1 μM) attenuated
cytotoxicity induced by ATO in H9c2 cells. Results of this
study suggest that morphine may have protective properties
in management of cardiac toxicity in patients who receive
ATO as an anti-cancer treatment.
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Introduction
Arsenic trioxide (ATO), as Chinese traditional medicine, is an
efficient therapeutic agent used in acute promyelocytic leuke-
mia (APL) and different types of human malignancies includ-
ing renal cell carcinoma, small-cell lung carcinoma, cervical
cancer, hepatocellular carcinoma, breast cancer, fibrosarcoma,
and neuroblastoma [1–3]. A growing body of evidence indi-
cates that mechanisms of action of ATO against malignant
cells may be related to activation of apoptosis signaling such
as pro-caspases [4], down-regulation of anti-apoptotic pro-
teins like Bcl-2 [5], inducing DNA damage [6], mitochondrial
membrane potential collapse, and increasing the reactive ox-
ygen species (ROS) formation [7–9]. Moreover, it has been
shown that ATO stimulates expression of apoptotic genes such
as p53-up-regulated modulator of apoptosis (PUMA) and Bcl-
2-associated X protein (BAX) [10, 11]. Our previous study
suggested that ATO induces apoptosis in an APL cell line
via up-regulation of p73 through suppression of nuclear factor
kappa B (NF-κB) which plays a key role in cell survival via
increased expression of anti-apoptotic genes such as survivin
[12–14], X-linked inhibitor of apoptosis protein (X-IAP), cel-
lular inhibitor of apoptosis proteins (cIAP1 and cIAP2) [15],
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and BCL2-like 1 (BCL-XL) [16] as well as increasing the lac-
tate dehydrogenase (LDH) leakage [6].
Despite advantages of ATO in treatment of several types of
malignancies, certain lethal and toxic side effects at therapeutic
doses have been reported such as sudden death [17], hepato-
toxicity [18], and also cardiotoxicity, which is manifested by
QTc prolongation and T-wave inversion and heart block
[19–21]. Also, recent evidence suggests that mitochondrial dys-
function plays a critical role in ATO-mediated cardiotoxicity via
increasing ROS production [22, 23]. Therefore, poly-therapy
for mitigating the ATO-induced cardiotoxicity seems a necessi-
ty based on aforementioned studies. In the current study, we
investigated possible protective effects of morphine against
ATO-induced cardiotoxicity in H9c2 cardiac muscle cells.
Material and Methods
Cell Line and Treatment
H9c2 cells were purchased from National Cell Bank of Iran
(NCBI; Tehran, Iran) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM), containing 0.15 % sodium bicar-
bonate, 10 % fetal bovine serum (Invitrogen), 0.11 % sodium
pyruvate, 0.45 % glucose, 20 μM L-glutamine, 50 μg/ml gen-
tamicin sulfate, 100 IU/ml penicillin, 10 μg/ml streptomycin,
and 25 ng/ml amphotericin B, without phenol red. Cells were
grown in 75-cm2 tissue culture flasks at 37 °C in a 5 % CO2
humidified incubator. H9c2 cells were treated with 0.5, 1, and
2 μM of ATO (Sina Darou, Tehran, Iran). An appropriate
amount of stock solution (0.5 mM in DMEM) of ATO was
added to culture medium to obtain the desired concentrations
and then incubated for 24, 48, and 72 h. The H9c2 cells were
exposed to 1μMofmorphine (Mac Farland&Smith, England)
4 h before ATO treatment and incubated for 24, 48, and 72 h.
Thiazolyl Blue Tetrazolium Bromide Assay
The inhibitory effects of ATO on growth and proliferation of
H9c2 cells were investigated by uptake of thiazolyl blue tet-
razolium bromide (MTT) by the living cells as described by
Momeny et al. [12] in 96-well plates (SPL Lifesciences,
Pocheon, Korea) at a concentration of 5000 cells/100 μl/well.
Bromodeoxyuridine Cell Proliferation Assay
The effects of ATO and morphine on DNA synthesis in
the H9c2 cells were studied using a colorimetric
bromodeoxyuridine (BrdU)-based cell proliferation
enzyme-linked immunosorbent assay (ELISA) kit (Roche
Molecular Biochemicals, Mannheim, Germany) at 450 nm
in different time intervals (24, 48, and 72 h) according to
the manufacturer’s instructions.
Measurement of ROS Formation
The rate of ROS formation was assayed by fluorescence spec-
t ropho tomete r (FLX 800, B ioTek , USA) us ing
dichlorodihydrofluorescein diacetate (DCFH-DA), a vital
fluorescent probe which enters to cells and is hydrolyzed to
2′,7′-dichlorofluorescein (DCFH2). Reaction with ROS forms
the highly fluorescent dichlorofluorescin (DCF) which ef-
fluxes from the cells. The fluorescence intensity of DCF
was measured by fluorescence plate reader at 485-nm ex-
citation and 538-nm emission wave lengths, respectively.
Results were communicated as fluorescence percentage of
control cells [24].
Caspase 3 Activity Assay
The effects of ATO and morphine on caspase-3 activity in
H9c2 cells were measured by colorimetric caspase-3 assay
kit (Sigma). This assay is based on hydrolysis of peptide sub-
strate (AC-DEVE-pNA) that is mediated by caspase-3 in a 96-
well plate at 37 °C for 2 h. Absorbance of pNA is measured
spectrophotometrically at 405-nm wavelength [25].
Cell-Based NF-κB Phosphorylation Measurement
The effects of ATO and morphine on NF-κB activation were
assessed by an ELISA assay based on phosphorylated NF-κB
form to total ratio at 450 nm (CASE Kit, Super Array
Bioscience, Frederick) as described with Janssen and Sen
[26].
Analysis of Gene Expression by Real-Time Quantitative
PCR
Fast Pure RNAKit (Takara Bio, Inc., Otsu, Japan) was used to
extract total RNA from the cultured cells. Changes in messen-
ger RNA (mRNA) expression of desired genes were evaluated
by real-time PCR after reverse transcription of 1 μg RNA
from each sample with Prime Script RT Reagent Kit (Takara
Bio) according to the manufacturer ’s instructions.
Quantitative real-time RT-PCR was done on a light cycler
instrument (Roche Diagnostics, Mannheim, Germany) using
SYBR Premix Ex Taq technology (Takara Bio). The PCR
assay was performed in a final volume of 20 μl containing
10 μl of SYBR Green master mix, 2 μl of cDNA samples,
0.5 μl of each forward and reverse primers (10 pmol), and 7 μl
of nuclease-free water (Qiagen, Hilden, Germany). Thermal
cycling environment involved an initial activation step for 30 s
at 95 °C followed by 45 cycles including a denaturation step
for 5 s at 95 °C and a combined annealing/extension step for
20 s at 60 °C. Melting curve investigation was applied to
confirm whether all primers yield a single PCR product.
Primers are mentioned in Table 1. Hypoxanthine
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phosphoribosyltransferase1 (HPRT1) was amplified as a nor-
malizer, and fold adjust in expression of each target mRNA
relative to HPRT1 was considered based on 2−ΔΔCt relative
expression formula [27].
Statistical Analysis
Data are expressed as mean± standard deviation (SD). All the
experiments were carried out in triplicate. For statistical anal-
ysis, the Student’s t test and one-way ANOVAwere applied.
In order to compare the groups, Dunnett’s multiple-
comparison test was used. P values less than 0.05 were con-
sidered significant.
Results
Morphine Antagonizes Inhibitory Effects of ATO
on Viability in H9c2 Cells
The activity of complex II was assessed using MTT test after
incubating H9c2 cells with different concentrations of ATO
(0.5, 1, and 2 μM). Figure 1 shows a significant decrease in
the mitochondrial metabolism of MTT to formazan (p<0.05)
following treatment with ATO (0.5, 1, and 2 μM) comparing
to control group in a concentration-dependent manner. Also,
pretreatment with morphine (1 μM) before ATO treatment
(4 h) significantly antagonized the inhibitory effects of ATO
on viability of H9c2 cells (P<0.05).
Morphine Reverses ATO-InducedROS (H2O2) Formation
in H9c2 Cells
As shown in Fig. 2, ATO (0.5–2 μM) induced significant ROS
(H2O2) formation in comparison with control group in a
concentration-dependent manner. A substantial increase in
mitochondrial ROS formation was observed in higher concen-
trations of ATO (2 μM). On the other hand, pretreatment with
morphine (1 μM) significantly attenuated ROS production
induced by ATO in H9c2 cells (P<0.05).
Morphine Antagonizes Inhibitory Effects of ATO on DNA
Synthesis in H9c2 Cells
As shown in Fig. 3, using the BrdU cell incorporation assay to
measure proliferation, the incorporation of BrdU in ATO-
treated cells apparently affects the subsequent cell growth in
H9c2 cells. Our results showed the inhibitory effect of ATO
(0.5, 1, and 2 μM) on DNA synthesis in concentration-
dependent manner. On the other hand, morphine (1 μM) could
antagonize the suppressive effects of ATO in desired concen-
tration on DNA synthesis in H9c2 cells.
Morphine Antagonizes ATO-Induced Caspase-3
Activation
As shown in Fig. 4, activity of caspase-3 enzyme (main me-
diator of apoptosis) was significantly increased (1.25–1.5-fold
comparing to control) in H9c2 cells, following 48 h of expo-
sure with ATO (1 and 2 μM). However, lower concentration
of ATO (0.5 μM) did not significantly increase ROS genera-
tion compared to control mitochondria (P>0.05). Significant
decrease in the caspase-3 activity was observed following the
treatment with morphine (1 μM) in the incubation time in all
of ATO treated groups (P<0.05), suggesting the role of oxi-
dative stress in mitochondrial permeability transition (MPT)-
mediated caspase-3 activation and finally cytochrome c
release.
Morphine Antagonizes with ATO-Induced Modulation
of Expression of Apoptosis Markers
As shown in Fig. 5, exposure with ATO (2 μM) for 48 h
significantly increased expression of apoptotic genes BAX
and PUMA compared to control groups (P < 0.001).
Furthermore, ATO significantly decreased expression of
anti-apoptotic genes BCL2, survivin, cIAP1, cIAP2, XIAP,
Table 1 Primer sequences for
real-time RT-PCR experiments Gene Forward primer (5′–3′) Reverse primer (3′–5′)
HPRT TGGACAGGACTGAACGTCTTG CCAGCAGGTCAGCAAAGAATTTA
PUMA GACCTCAACGCACAGTACGAG AGGAGTCCCATGATGAGATTGT
BAX CGAGAGGTCTTTTTCCGAGTG GTGGGCGTCCCAAAGTAGG
Bcl-2 CGGTGGGGTCATGTGTGTG CGGTTCAGGTACTCAGTCATCC
Survivin CCAGATGACGACCCCATAGAG TTGTTGGTTTCCTTTGCAATTTT
cIAP2 TCCTGGATAGTCTACTAACTGCC GCTTCTTGCAGAGAGTTTCTGAA
XIAP ATAGTGCCACGCAGTCTACAA AGATGGCCTGTCTAAGGCAAA
Bcl-XL GAGCTGGTGGTTGACTTTCTC AGATGGCCTGTCTAAGGCAAA
cIAP1 GTCCTCTGCGGAAGTGACTC GGAAACTGGCGCTGGTATAA
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and BCL-XL in comparison with control groups (P<0.05 and
P<0.01). In addition, our results showed that morphine sig-
nificantly reversed the decrease in expression of apoptotic
genes BAX and PUMA (P < 0.001) and also increased
expression of anti-apoptotic genes BCL2 and survivin in com-
parison with control group (P < 0.05 and P < 0.01,
respectively).
Morphine Reverses ATO-Mediated Suppression of NF-κB
Activation in H9c2 Cells
For determining the relationship between inhibition of NF-κB
and ATO-induced apoptosis, we used different concentration
of ATO (0.5–2 μM) and pretreatment with morphine (1 μM)
in H9c2 cell line. As shown in Fig. 6, NF-κB activity signif-
icantly decreased following higher concentration of ATO (1
and 2 μM) compared to control group (P < 0.05).
Furthermore, pretreatment with morphine (1 μM) significant-
ly reversed ATO-mediated suppression of NF-κB activation in
H9c2 cells after 48 h.
Discussion
Morphine, as an analgesic drug, has been reported to have
antioxidant and anti-apoptotic effects including ROS scaven-
ger capacity, inhibition of NADPH oxidase activity, and in-
creasing of glutathione levels in neuronal and heart cells
Fig. 1 MTT assay was applied to estimate the proliferative capacity of
H9c2 cells over 72 h of treatment with escalating concentrations of ATO
(a) and ATO plus morphine (1 μM) (b). Data are expressed as mean
± SEM and were analyzed by one-way ANOVA and Tukey’s post hoc
test. *P< 0.05, **P< 0.01, and ***P< 0.001 compared to control group
Fig. 2 The level of ROS generation in H9c2 cells exposed to different
concentrations of ATO and ATO plus morphine (1 μM) for 48 h. Data are
expressed as mean ± SEM and were analyzed by one-way ANOVA and
Tukey’s post hoc test. #P< 0.05, ##P< 0.01, and ###P< 0.001 compared to
control group. **P< 0.01 and ***P< 0.001 compared to ATO-related
exposed groups
Fig. 3 The effects of enhancing doses of ATO (a) and ATO plus
morphine (1 μM) (b) on DNA synthesis in H9c2 cells over 72 h of
treatment. Data are expressed as mean ± SEM and were analyzed by
one-way ANOVA and Tukey’s post hoc test.*P< 0.05, **P< 0.01, and
***P< 0.001 compared to control group
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[28–31]. Based on previous studies, the inhibitory effect of
morphine on glutamate-induced astrocyte toxicity is related
to intracellular redox reactions which are not prevented by
naloxone, suggesting that opioids have receptor-independent
mechanisms [32]. Moreover, there are several reports indicat-
ing that opioid agonists exert strong protective effects on
ischemia-reperfusion conditions in the heart [33]. It has been
reported that activation of opioid receptors induces
hibernation-like states that increase organ stress resistance
via induction of low energy consumption and activation of
ATP-sensitive K+ channels [34, 35]. Besides, morphine in-
duces a preconditioning effect on C8-B4, a microglial cell line
via decreasing of LDH release, an indicator of cell toxicity, as
well as decreasing the release of TNF-α [35, 36]. Our results
are corroborated with evidence indicating that protective role
of morphine in ATO-induced oxidative stress is associated
with changes in antioxidant activity (GSH level and superox-
ide dismutase activity) and inhibition of generation of super-
oxide anion radicals [28, 37].
The concentration ranges of ATO (0.5–2 μM) and mor-
phine (1 μM) were selected on the basis of a series of pilot
studies in our laboratory [12, 38, 39]. Although the concen-
trations of ATO used in this study might seem relatively high,
in vitro research works in mechanistic toxicology simulate
chronic/low concentration, problems with acute/high-
concentration condition in cell lines which cannot be kept
alive or operate more than maximum 3–4 weeks following
treatment. Obtaining statistically valid results and determina-
tion of toxicity mechanisms from in vitro or in vivo test (in
small groups) require the administration of relatively large
doses so that the effect will occur frequently enough to be
detected [40].
Several lines of research have revealed that ATO is used as
an anti-tumor drug, especially in treatment of APL; hemato-
poietic malignancies; and solid tumors such as liver, prostate,
breast, and gastric cancers [41–44]. However, there are report-
ed side effects of ATO in heart including T-wave and A-V
block [45, 46].
Our data confirmed decreased activity of succinate dehy-
drogenase (SDH), a constitutive molecule of complex II in
mitochondrial electron transfer chain through reduction of
MTT to formazan [8]. In addition, it was also found that
ATO significantly inhibited mitochondrial complex II activity
in a concentration-dependent manner (P<0.05) in H9c2 cells
that indicates the disturbance in electron chain transfer. Also,
the present data showed that pretreatment with morphine be-
fore ATO effectively reduced complex II activity in
cardiomyocytes. Evidence suggests that main site of
Fig. 4 The caspase 3 activity in H9c2 cells exposed to increasing doses
of ATO and ATO plus morphine (1 μM) for 48 h. Data are expressed as
mean ± SEM and were analyzed by one-way ANOVA and Tukey’s post
hoc test. ###P< 0.001 compared to control group. ***P< 0.001 compared
to ATO-related exposed groups
Fig. 5 The expression of apoptotic and anti-apoptotic genes in H9c2
cells exposed to ATO (2 μM) and ATO plus morphine (1 μM) for 48 h.
Data are expressed as mean ± SEM and were analyzed by one-way
ANOVA and Tukey’s post hoc test. *P < 0.5, **P < 0.01, and
***P < 0.001 compared to ATO-related exposed groups. #P < 0.5,
##P< 0.01, and ###P< 0.001 compared to control groups
Fig. 6 The NF-κB activity in H9c2 cells exposed to escalating
concentrations of ATO and ATO plus morphine (1 μM) for 48 h. Data
are expressed as mean ± SEM and were analyzed by one-way ANOVA
and Tukey’s post hoc test. #P< 0.05 and ##P< 0.01 compared to control
group. ***P< 0.001 compared to ATO-related exposed groups
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MTT reduction is mitochondrial complex II and activity
of this complex is responsible for most cellular reduc-
tion capacity and criteria for evaluation of electron
transfer chain [47].
Besides, morphine antagonized the suppressive effects of
ATO onDNA synthesis, explaining the increased resistance of
cardiomyocytes against ATO-induced apoptosis. In addition,
we found a significant increase in ROS generation in H9c2
cells following exposure with ATO (0.5–2 μm). Previous
studies show that mitochondrial respiratory chain complex
is the main source of ROS production [48] and impair-
ment in any component of respiratory chain could cause
mitochondrial dysfunction followed by oxidative stress
and cell injury [49], which further causes tissue damage
and organ dysfunction.
Also, increasing of ROS production leads to MPT pore
opening and release of cytochrome c that triggers caspase-3
activation as the main initiator of apoptotic pathways [50].
Therefore, the caspase-3 activity was measured in H9c2 cells
when incubated with ATO and morphine. Similarly, a recent
in vitro study on cardiac cells showed that exposure to mor-
phine decreased caspase-3 activation in doxorubicin-induced
oxidative stress via mitochondrial dysfunction [51–54]. It has
been suggested that ATO causes cardiac toxicity similar to
doxorubicin via intrinsic and extrinsic pathways of apoptosis
which affected mitochondrial damage, and this study sug-
gested that morphine could reverse ATO-induced cytotoxicity.
It seems that the protective effect of morphine against ATO
was partly mediated via inhibiting of MPT pore opening [55].
In tumor cells, constitutive NF-κB activity is responsible
for proliferation and to protect cells from apoptosis and drug
resistance [56]. Previous studies have shown that ATO sup-
presses NF-κB pathway which has a key role in tumorigenesis
via induction of transcriptional level in apoptotic genes such
as PUMA and BAX [10, 11]. In the present study, our data
showed that morphine increased the level of NF-κB, suggest-
ing that morphine is able to induce a decrease in expression of
apoptotic genes, an increase in the level of anti-apoptotic
markers, and and a decrease in caspase-3 activity in ATO-
treated cells.
Conclusion
Due to the fact that morphine exerts protective effects on
ATO-exposed cardiomyocytes, its utility can be a new strategy
for protection and/or management of cardiac toxicity in pa-
tients who receive ATO as an anti-cancer treatment.
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